Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Transcode Therapeutics Inc (RNAZ)

Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,225
  • Shares Outstanding, K 6,622
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,550 K
  • 60-Month Beta 0.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.34
Trade RNAZ with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -199.45
  • Most Recent Earnings $-0.65 on 05/15/24
  • Next Earnings Date 08/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.58
  • Number of Estimates 1
  • High Estimate -0.58
  • Low Estimate -0.58
  • Prior Year -131.60
  • Growth Rate Est. (year over year) +99.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8501 +2.12%
on 07/03/24
1.6686 -47.97%
on 06/04/24
-0.7519 (-46.41%)
since 06/03/24
3-Month
0.4200 +106.69%
on 04/24/24
2.0100 -56.81%
on 05/10/24
+0.2181 (+33.55%)
since 04/03/24
52-Week
0.4200 +106.69%
on 04/24/24
128.0000 -99.32%
on 09/25/23
-92.7319 (-99.07%)
since 07/03/23

Most Recent Stories

More News
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END

BMY : 40.06 (-0.96%)
ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
VACC : 5.00 (+11.36%)
BPTS : 8.22 (-15.28%)
RNAZ : 0.8681 (-7.65%)
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - There has been a rise in the prevalence of cancer in the past several years. Overall, there is a rapid...

ONC.TO : 1.41 (+2.92%)
ONCY : 1.0100 (+2.02%)
VACC : 5.00 (+11.36%)
BPTS : 8.22 (-15.28%)
RNAZ : 0.8681 (-7.65%)
BMY : 40.06 (-0.96%)
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END

ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
GILD : 66.59 (-2.65%)
RXDX : 199.92 (+0.09%)
RNAZ : 0.8681 (-7.65%)
BMY : 40.06 (-0.96%)
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to a report from Global Market Insights the Breast Cancer Therapeutics Market size, which...

ONC.TO : 1.41 (+2.92%)
ONCY : 1.0100 (+2.02%)
GILD : 66.59 (-2.65%)
BMY : 40.06 (-0.96%)
RXDX : 199.92 (+0.09%)
RNAZ : 0.8681 (-7.65%)
Biotech Sees Massive Rally On Major Announcement

A Boston-based %Biotech company caught the attention of the trading community on Wednesday after it was announced that the company withdrew the Registration Statement on Form S-1 it filed with the U.S....

RNAZ : 0.8681 (-7.65%)
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END

ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
MACK : 15.13 (unch)
NRBO : 4.47 (-4.48%)
MRK : 125.85 (-1.46%)
RNAZ : 0.8681 (-7.65%)
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market...

ONC.TO : 1.41 (+2.92%)
ONCY : 1.0100 (+2.02%)
MACK : 15.13 (unch)
NRBO : 4.47 (-4.48%)
MRK : 125.85 (-1.46%)
RNAZ : 0.8681 (-7.65%)
Positive Results Causes Pop In Biotech Stock

A Boston-based %Biotech company really captured the attention of traders on Wednesday after the it reported Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma....

RNAZ : 0.8681 (-7.65%)
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA...

RNAZ : 0.8681 (-7.65%)
TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference

BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright...

RNAZ : 0.8681 (-7.65%)

Business Summary

TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 1.0434
2nd Resistance Point 1.0012
1st Resistance Point 0.9346
Last Price 0.8681
1st Support Level 0.8258
2nd Support Level 0.7836
3rd Support Level 0.7170

See More

52-Week High 128.0000
Fibonacci 61.8% 79.2644
Fibonacci 50% 64.2100
Fibonacci 38.2% 49.1556
Last Price 0.8681
52-Week Low 0.4200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar